Bendell, J., Eckhardt, G. S., Hochster, H. S., Morris, V. K., Strickler, J., Kapoun, A. M., … Munster, P. (2016). Initial results from a phase 1a/b study of OMP-131R10, a first-in-class anti-RSPO3 antibody, in advanced solid tumors and previously treated metastatic colorectal cancer (CRC). In European Journal of Cancer (Vol. 69, pp. S29–S30). Elsevier BV. https://doi.org/10.1016/s0959-8049(16)32668-5

Bendell, J., G. S. Eckhardt, H. S. Hochster, V. K. Morris, J. Strickler, A. M. Kapoun, M. Wang, et al. “Initial results from a phase 1a/b study of OMP-131R10, a first-in-class anti-RSPO3 antibody, in advanced solid tumors and previously treated metastatic colorectal cancer (CRC).” In European Journal of Cancer, 69:S29–30. Elsevier BV, 2016. https://doi.org/10.1016/s0959-8049(16)32668-5.

Bendell J, Eckhardt GS, Hochster HS, Morris VK, Strickler J, Kapoun AM, et al. Initial results from a phase 1a/b study of OMP-131R10, a first-in-class anti-RSPO3 antibody, in advanced solid tumors and previously treated metastatic colorectal cancer (CRC). In: European Journal of Cancer. Elsevier BV; 2016. p. S29–30.

Bendell, J., et al. “Initial results from a phase 1a/b study of OMP-131R10, a first-in-class anti-RSPO3 antibody, in advanced solid tumors and previously treated metastatic colorectal cancer (CRC).” European Journal of Cancer, vol. 69, Elsevier BV, 2016, pp. S29–30. Crossref, doi:10.1016/s0959-8049(16)32668-5.

Bendell J, Eckhardt GS, Hochster HS, Morris VK, Strickler J, Kapoun AM, Wang M, Xu L, McGuire K, Dupont J, Faoro L, Munster P. Initial results from a phase 1a/b study of OMP-131R10, a first-in-class anti-RSPO3 antibody, in advanced solid tumors and previously treated metastatic colorectal cancer (CRC). European Journal of Cancer. Elsevier BV; 2016. p. S29–S30.